Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.34 |
| ▸ | KDM1A | O60341 | 3/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | DRD4 | P21917 | 1/20 | 0.33 |
| ▸ | PBK | Q96KB5 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | BTK | Q06187 | 6/20 | 0.32 |
| ▸ | TOP2A | P11388 | 2/20 | 0.32 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3596238 | 0.81 | PARP1 (0.37) | MAPK1OPRK1HDAC4PBKTOP2A | |
| SCHEMBL3604698 | 0.81 | MAPK1 (0.43) | MAPK1OPRK1HDAC4KDM1AHDAC6 | |
| SCHEMBL3611921 | 0.77 | MAPK1 (0.44) | MAPK1OPRK1HDAC4KDM1AHDAC6 | |
| SCHEMBL3612662 | 0.77 | ADORA1 (0.45) | MAPK1OPRK1HDAC4KDM1A | |
| SCHEMBL3612512 | 0.77 | HTR6 (0.38) | MAPK1OPRK1HDAC4HDAC6DRD4 | |
| SCHEMBL3599370 | 0.76 | CDK2 (0.41) | MAPK1OPRK1HDAC4HDAC6PBK | |
| SCHEMBL3606634 | 0.76 | PARP1 (0.41) | HDAC4HDAC6PARP1 | |
| SCHEMBL3595862 | 0.75 | CDK2 (0.42) | HDAC4DRD4TOP2APARP1 | |
| SCHEMBL3606656 | 0.74 | PARP1 (0.41) | MAPK1OPRK1HDAC4HDAC6PARP1 | |
| SCHEMBL3601242 | 0.74 | KDR (0.40) | HDAC4HDAC6PBKSCN9ABTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100035862-A1 | NOVEL AZA-CYCLIC INDOLE-2-CARBOXAMIDES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035862-A1 | NOVEL AZA-CYCLIC INDOLE-2-CARBOXAMIDES AND METHODS OF USE THEREOF | IDO2, IDO1, INMT | MAPK1 4292/4885OPRK1 609/4885HDAC4 134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.